MUC1 immunotherapy is here to stay
- 24 September 2012
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Biological Therapy
- Vol. 13 (1), 35-49
- https://doi.org/10.1517/14712598.2012.725719
Abstract
(2013). MUC1 immunotherapy is here to stay. Expert Opinion on Biological Therapy: Vol. 13, No. 1, pp. 35-49. doi: 10.1517/14712598.2012.725719Keywords
This publication has 60 references indexed in Scilit:
- Cytotoxic T-lymphocyte Immunotherapy for Ovarian CancerJournal of Immunotherapy, 2012
- MUC1 Protein Expression in Tumor Cells Regulates Transcription of Proinflammatory Cytokines by Forming a Complex with Nuclear Factor-κB p65 and Binding to Cytokine PromotersJournal of Biological Chemistry, 2011
- Intradermal Vaccinations With RNA Coding for TAA Generate CD8+ and CD4+ Immune Responses and Induce Clinical Benefit in Vaccinated PatientsMolecular Therapy, 2011
- MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transitionOncogene, 2010
- Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909Cancer Immunology, Immunotherapy, 2010
- Mucins in cancer: function, prognosis and therapyNature Reviews Cancer, 2009
- Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancerOncogene, 2009
- Humoral immune response to abnormal MUC1 in subjects with colorectal adenoma and cancerMolecular Immunology, 2009
- A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung CancerJournal of Thoracic Oncology, 2008
- Upregulated expression of complement inhibitory proteins on bladder cancer cells and anti‐MUC1 antibody immune selectionInternational Journal of Cancer, 2008